Top

Published in:

01-11-2013 | Original Article

Clinical significance of T_reg cell frequency in acute myeloid leukemia

Authors: Wenjuan Yang, Yunxiao Xu

Published in: International Journal of Hematology | Issue 5/2013

Abstract

This study was designed to investigate the clinical significance of peripheral blood CD4⁺ CD25⁺ CD127 low-regulatory T (T_reg) cells in acute myeloid leukemia (AML) patients. T_reg cells in the peripheral blood of 80 AML patients and 35 age-matched healthy controls were counted by flow cytometry. Correlations between the frequency of circulating T_reg cells and disease status, treatment outcome, or prognosis were evaluated. The percentages of T_reg cells in patients at diagnosis and during refractory/relapse were significantly higher than that in healthy controls. There was no significant difference in the percentages of T_reg cells between patients in remission and healthy controls. After six cycles of chemotherapy, the percentage of T_reg cells in patients who achieved complete remission was significantly lower than that in patients at diagnosis, but there was no difference in T_reg frequency between refractory/relapse patients and patients at diagnosis. T_reg cells in the peripheral blood of AML patients may play a suppressive role in host antitumor immune response. The frequency of T_reg cells in peripheral blood may thus be used as a biomarker for predicting sensitivity to chemotherapy and prognosis of AML patients. Additionally, T_reg number in peripheral blood could be used to monitor disease status and evaluate disease progression.

Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist. 2009;14:240–52.PubMedCrossRef

Kanakry CG, Hess AD, Gocke CD, Thoburn C, Kos F, Meyer C, et al. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligo clonal expansion of regulatory T cells. Blood. 2011;117:608–17.PubMedCrossRef

Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118:5084–95.PubMedCrossRef

Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009;15:3325–32.PubMedCrossRef

Pandolfi F, Cianci R, Lolli S, Dunn IS, Newton EE, Haggerty TJ, et al. Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol. 2008;21:493–500.PubMed

Robak T, Wrzesie′n-Ku′s A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2002;43:281–91.PubMedCrossRef

Mato AR, Morgans A, Luger SM. Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol. 2008;15:108–14.PubMedCrossRef

Kelley TW, Parker CJ. CD4(+)CD25(+)Foxp3(+) regulatory T cells and hematologic malignancies. Front Biosci (Schol Ed). 2010;2:980–92.CrossRef

Wang X, Zheng J, Liu J, Yao J, He Y, Li X, et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 2005;75:468–76.PubMedCrossRef

10.

Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328–39.PubMedCrossRef

11.

Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol. 2010;11:38.PubMedCrossRef

12.

Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25⁻ into CD25⁺ T regulatory cells. Blood. 2007;109:2871–7.PubMed

13.

Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, et al. Tumor derived CD4⁻CD25⁻ regulatory T cell suppression of dendritic cell function involves TGFbeta and IL-10. Cancer Immunol Immunother. 2007;56:48–59.PubMedCrossRef

14.

Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med. 2008;205:2221–34.PubMedCrossRef

15.

Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW, et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer. 2008;122:1794–802.PubMedCrossRef

16.

Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118:5084–95.PubMedCrossRef

17.

Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804–11.PubMedCrossRef

18.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.PubMedCrossRef

19.

Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007;56:1743–53.PubMedCrossRef

20.

Zhang S, Han Y, Wu J, Yu K, Bi L, Zhuang Y, et al. Elevated frequencies of CD4⁺ CD25⁺ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011;129:1373–81.CrossRef

21.

Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4⁺CD25⁺regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–8.PubMedCrossRef

22.

Chu Y, Wang LX, Yang G, Ross HJ, Urba WJ, Prell R, et al. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother. 2006;29:367–80.PubMedCrossRef

Title: Clinical significance of Treg cell frequency in acute myeloid leukemia
Authors: Wenjuan Yang
Yunxiao Xu
Publication date: 01-11-2013
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-013-1436-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission

Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group

Enlargement of bilateral kidneys by infiltration of leukemic cells in acute lymphoblastic leukemia at relapse after allogeneic hematopoietic stem cell transplantation

Profound plasmacytosis in a patient with dengue

Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin’s lymphoma

Detection of acquired hemoglobinopathy in children with hematological malignancies at disease onset: results form a national referral centre

Keynote webinar | Spotlight on antibody–drug conjugates in cancer